New series of fused pyrazolopyridines: Synthesis, molecular modeling, antimicrobial, antiquorum-sensing and antitumor activities

• Published in: Bioorganic chemistry Vol. 92; pp. 103109 - 103126
• Main Authors: El-Gohary, N.S., Hawas, S.S., Gabr, M.T., Shaaban, M.I., El-Ashmawy, M.B.
• Format: Journal Article
• Language: English
• Published: SAN DIEGO Elsevier Inc 01.11.2019; Elsevier
• Subjects: Antimicrobial; Antiquorum-sensing; Antitumor; Biochemistry & Molecular Biology; Chemistry; Chemistry, Organic; DNA-binding; Fused pyrazolopyridines; Life Sciences & Biomedicine; Molecular modeling; Physical Sciences; Science & Technology; Topoisomerase IIβ; Fused pyrazolopyridines; Antimicrobial; Molecular modeling; Antiquorum-sensing; Antitumor; Topoisomerase IIβ; DNA-binding; CYTOTOXIC ACTIVITIES; RAPID COLORIMETRIC ASSAY; TOPOISOMERASE-II; ONE-POT SYNTHESIS; DRUG DISCOVERY; CHROMOBACTERIUM-VIOLACEUM; HETEROCYCLIC SYNTHESIS; ANTICANCER; BIOLOGICAL EVALUATION; Topoisomerase II beta; DERIVATIVES
• ISSN: 0045-2068; 1090-2120
• DOI: 10.1016/j.bioorg.2019.103109

[Display omitted] •New series of fused pyrazolopyridine analogs were prepared.•The new analogs were evaluated for antimicrobial and antitumor activities.•Analogs 4a, 7a and 7b showed good and broad-spectrum antimicrobial activity.•Analogs 7a and 7b displayed the highest antitumor activity.•Analogs 7a and 7b demonstrated strong DNA-binding affinity and promising TOP IIβ inhibitory activity. New series of fused pyrazolopyridines were prepared and assessed for antimicrobial, antiquorum-sensing and antitumor activities. Antimicrobial evaluation toward selected Gram-positive bacteria, Gram-negative bacteria and fungi indicated that 5-phenylpyrazolopyridotriazinone 4a has good and broad-spectrum antimicrobial activity. In addition, 5-(4-chlorophenyl)pyrazolopyridotriazinone 4b and 5-(4-(dimethylamino)phenyl)pyrazolopyridotriazinone 4c exhibited good activity against the selected Gram-positive bacteria and A. fumigatus, whereas 5-amino-4-phenylpyrazolopyridopyrimidine 6a demonstrated good activity against B. cereus and P. aeruginosa. Furthermore, 6-amino-5-imino-4-phenylpyrazolopyridopyrimidine 7a and 6-amino-4-(4-chlorophenyl)-5-iminopyrazolopyridopyrimidine 7b demonstrated promising activity against the tested Gram-negative bacteria and fungi, and moderate activity against Gram-positive bacteria. Antiquorum-sensing screening over C. violaceum illustrated that 4a, 6a and 7a-c have strong activity. In vitro antiproliferative assessment of the new derivatives against HepG2, HCT-116 and MCF-7 cancer cells revealed that 7a is the most active analog against all tested cell lines. Likewise, 3,7-dimethyl-4-phenylpyrazolopyridopyrimidinone 2a and 6-amino-4-(4-chlorophenyl)-5-iminopyrazolopyridopyrimidine 7b manifested strong activity against all examined cell lines. In vivo antitumor testing of 2a, 7a and 7b against EAC cells in mice indicated that 7a has the highest activity. Cytotoxicity toward WI38 and WISH normal cells was also assessed and results assured that all of the investigated analogs have lower cytotoxicity than doxorubicin. DNA-binding affinity and topoisomerase IIβ inhibitory activity were evaluated, and results revealed that 5b, 7a and 7b bind strongly to DNA; in addition, 2a, 4a, 7a and 7b manifested higher topoisomerase IIβ inhibitory activity than that of doxorubicin. Analogs 5b, 7a and 7b were docked into topoisomerase IIβ, and results indicated that 7a and 7b have the highest binding affinity toward topoisomerase IIβ. In silico simulation studies referred that most of the new analogs comply with the optimum needs for good oral absorption. Also, computational carcinogenicity evaluation was predicted.